Le Lézard
Classified in: Health
Subject: ACC

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova


STOCKHOLM, April 23, 2021 /PRNewswire/ -- Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.

Emollivet develops animal care products based on Lipidor's patented AKVANO technology. The company was funded in 2020 to focus on commercializing animal care products. Since Stina Linge was recruited as CEO last autumn, development in Emollivet has accelerated.

Through the open call "Innovative startups step 1", Vinnova finances start-ups in Sweden that want to contribute to sustainable growth in a global market, with scalable operations that are based on innovative products or services. In the spring round, 934 applications were submitted to Vinnova and Emollivet is one of the selected companies awarded funds through the open call.

Emollivet's CEO Stina Linge: "This shows that Vinnova sees potential in our growing business in the same way as we do ourselves. We're very much looking forward to being able to accelerate this work, and we encourage pet owners with skin problems to contact us for interaction during our test period". 

The information was submitted for publication, through the office of the contact person, on 23 April 2021, at 8.15am CEST.

For more information, please contact
Ola Holmlund
CEO
Phone: +46 72 50 70 369
E-mail: [email protected]

Stina Linge
CEO
Emollivet AB
Telephone: +46 (0)70 224 75 44
Email: [email protected]

Certified Adviser
Erik Penser Bank AB
Telefon: +46 (0)8 463 83 00
E-post: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/lipidor/r/lipidor-s-subsidiary-emollivet-takes-the-next-step-towards-launch-and-receives-funding-from-vinnova,c3331936

The following files are available for download:

https://mb.cision.com/Main/17081/3331936/1406121.pdf

210423 PR Emollivet innovative startups EN

 

SOURCE Lipidor


These press releases may also interest you

at 05:12
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Donates Some 3,200 Units of Blood Pressure Monitors to Global Blood Pressure Screening Campaign on World Hypertension Day
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
RaySearch publishes Annual Report for 2023
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
ZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica publishes Annual Report 2023
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Interim report January-March 2024: Medicover
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

More news about Health...


News published on and distributed by: